Forskolin

For research use only. Not for use in humans.

製品コードS2449 別名:Coleonol

Forskolin化学構造

分子量(MW):410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 25200 あり
JPY 20200 あり
JPY 46800 あり
JPY 63400 あり
JPY 96600 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(42)

製品安全説明書

cAMP阻害剤の選択性比較

生物活性

製品説明 Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.
ターゲット
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外試験

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 NGDqbohHfW6ldHnvckBCe3OjeR?= NFvFPYcyOCEQvF2= M3XCb|YhcA>? M1zONIlv[3KnYYPld{BxcG:|cHjvdplt[XSrb36gc4Yhd3[ncnX4dJJme3OnZDDLUGhNOyCjdDDTOFM{ MlP6NlY1OzV2OUi=
Mo-DCs MlHySpVv[3Srb36gRZN{[Xl? MlPyOVAh|ryP MX6yOQKBkWh? NWq0VFd2eHKxbX;0[ZMhUUxvMkOgdJJw\HWldHnvckBqdiC2aHWgd5Vx\XKwYYThcpQhd2Zieontc5NidiC|dHnteYxifGWmIF3vMWREe8Li NGXXVIYzPjRzMkm0PC=>
RBMECs  MojGSpVv[3Srb36gRZN{[Xl? MmrIOeKh|ryP MmnoNeKhcA>? MWricI9kc3NidHjlJHJi[zFiaX7hZ5RqfmG2aX;uJIlv\HWlZXSgZpkhTU2DUD3JTS=> M{S1e|I3OzV6MEO5
INA-6 MmP3R4VtdCCYaXHibYxqfHliQYPzZZk> MXKwMVExOCEQvF2= MXO3NwKBkWh? NFflVmVqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NYm5U4ZXOjZ|ME[2NlQ>
OPM-2 NGLlXndE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NV;GUGxnOC1zMECg{txO NUHpTZNXPzMkgJno MYDpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MoLwNlY{ODZ4MkS=
U266 NInjZldE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mlm3NE0yODBizszN MYq3NwKBkWh? NGnnTZNqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NWXRO4dwOjZ|ME[2NlQ>
H929 Mm\NR4VtdCCYaXHibYxqfHliQYPzZZk> M{jSeFAuOTByIN88US=> NGrON2I4OuLCiXi= MVTpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= M3XXZVI3OzB4NkK0
RPMI 8226 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1;SOlAuOTByIN88US=> MU[3NwKBkWh? NHT2dWJqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NXToWo9sOjZ|ME[2NlQ>
MDCK  MYnGeY5kfGmxbjDBd5NigQ>? NVr0OZJbOTBiwsXN MVuyOEBp M4n1bGROW09? MoPzeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhXEeILd8yNUBidmRiQ2THSuKh MnHaNlYzODJ|NUK=
MDCK  Ml3xSpVv[3Srb36gRZN{[Xl? NGnTcpQyOCEEtV2= NW\YNFN2OjRiaB?= MUPEUXNQ MlfmbY5pcWKrdIOgeIhmKGmwY4LlZZNm\CCneIDy[ZN{cW:wIH;mJGZPKGOjdYPl[EBjgSCWR1[t{tIy MXGyOlIxOjN3Mh?=
Spinal cords  NF71b3NHfW6ldHnvckBCe3OjeR?= M1;2fVHDqM7:TR?= NHXLbpE{OCCvaX6= NETMPGh{fGmvdXzheIV{KGODTWCgcIV3\Wy| NYrZWpk2OjZzMk[5NlY>
BeWo  M4C5OmZ2dmO2aX;uJGF{e2G7 MoK4NlXjiIoQvF2= MmXtNlQwPDhxN{KgbC=> NFPaVXFt\WGmczD0c{BidiCrbnPy[YF{\SCrbjD0bIUh\XiycnXzd4lwdiCxZjDveIhmeiCodYPpc44hdWG{a3Xydy=> NXrPfXRqOjZyNUO1OFk>
bovine oocytes MXzGeY5kfGmxbjDBd5NigQ>? MWmxNFDDqM7:TR?= NVHyZnV4OTMEoHi= MXHpcohq[mm2czD0bIUh\W[oZXP0JI9nKE6SUFGgZY5lN2:{IF7QVGMhfG9ic4TpcZVt[XSnIILld5VueHSrb36gc4YhdWWrb4Ppdy=> MX[yOlA2OTZzMR?=
Caco-2  NXzOZoZLTnWwY4Tpc44hSXO|YYm= M4e5[|AvOS9zL{GwJO69VQ>? NYjzco54OjEEoH3pci=> Mmq5bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJIlvfHKjY3XscJVt[XJiY1HNVEBt\X[nbIO= MXeyOlA1QTFyMh?=
Caco-2  NGe5W2FHfW6ldHnvckBCe3OjeR?= M1PoS|AvOS9zL{GwJO69VQ>? M4[3TFI1KGh? MUHpcoNz\WG|ZYOgUXJROiCycn;0[YlvKGyndnXs MX2yOlA1QTFyMh?=
AML-12  Mnu1SpVv[3Srb36gRZN{[Xl? NX;5cnNCOjBizszN M3uwTlMhcA>? NGXpZVR2eHKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIHzleoVteyCjdDDUbJIuPDFzIHHu[EBU\XJvNEmz M1nodlI3ODR6OUi1
AML-12  MnmySpVv[3Srb36gRZN{[Xl? MWiyNEDPxE1? M4LMdVEuQCCq MX;pcoNz\WG|ZYOg[4x2[2:|ZTDwdo9lfWO2aX;u NUW4PFF[OjZyNEi5PFU>
AML-12  MVzGeY5kfGmxbjDBd5NigQ>? MVGyNEDPxE1? M37wR|MhcA>? NV\2O2EyfXBvcnXneYxifGW|wrDQ[4My[S{EoGDldINsNCCjbnVCpGc3eGQEoH3SUmEhdGW4ZXzz MnvLNlYxPDh7OEW=
AML-12  MkLZSpVv[3Srb36gRZN{[Xl? MY[yNEDPxE1? MkS5N{Bp M3rnWYlv\HWlZYOgeIhmKGSncHjvd5Bpd3K7bHH0bY9vKG:oIFPSWGMzyqB? MWOyOlA1QDl6NR?=
RBMECs NYXsSGY6TnWwY4Tpc44hSXO|YYm= MljuOeKh|ryP M2r3XVEhcA>? Mnq0bY5pcWKrdIOgSW1CWC2LST3pcoR2[2WmIHnuZYN1cX[jdHnvckBw\iCUYYCxxsA> M2\GbFI3ODR2Nk[z
EndoC-βH1 NG\Wc5JHfW6ldHnvckBCe3OjeR?= M1\FVVXDqM7:TR?= NFHvbmYyKGh? MUTwc5RmdnSrYYTld{BodHWlb4PlMYlv\HWlZXSgbY5{fWyrbjDz[YNz\XSrb36gbY4hfGinIIDy[ZNmdmOnIH;mJIdtfWOxc3W= NV;pXJVLOjZyMki1OlI>
EndoC-βH1 NGfrNXJHfW6ldHnvckBCe3OjeR?= NGX5VoI2yqEQvF2= NWW1e2t1OSCq MmnwcIVi\HNidH:gZUB{fHKxbnegZ2FOWCCrbnPy[YF{\Q>? Ml3pNlYxOjh3NkK=
SH-SY5Y MUjGeY5kfGmxbjDBd5NigQ>? NFe3dJM{OCEQvF2= NVTkUHpJOzBibXnu NHPsb4tFVVOR NHHlPFF{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUh[WO2aY\heIlwdiCxZjDQT2E> NU[3N2lDOjZyMkWxN|c>
PC-3 MlvGSpVv[3Srb36gRZN{[Xl? MX60NEDDvU1? MVGyJIg> MV\EUXNQ M2S4Voxm[WS|IITvJHBROkFiYXP0bZZifGmxbh?= M{[1dFI3ODJ|OEO2
PC-3 NGG1dYpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF3kRWk1OCEEtV2= M2n5flI1NzR6L{eyJIg> NUm3NJV5TE2VTx?= Mmjw[IVkemWjc3XzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl? MVKyOlAzOzh|Nh?=
SCG NYjVS|c2TnWwY4Tpc44hSXO|YYm= NEPxTowzOCEQvF5CpC=> NX7TO2FZTE2VTx?= NWHPd2pqemW4ZYLzbYJtgSC|dYDwdoV{e2W|IFnLWkB4cXSqIHGgTWM2OCCxZjCyOE41KM7:TR?= NWjGSWR4OjV7NkKxN|I>
HEK-293 M4rKO2Z2dmO2aX;uJGF{e2G7 M3m4TFM2KM7:TdMg NWnjeVhXTE2VTx?= MmTYbY5lfWOnczDhJINwdnOyaXP1c5V{KOLCnHnuZYN1cX[jdHnvcwKBpSCxZjD0bIUhU3Z{LkGgZ5VzemWwdB?= NYj6PXlWOjV7NkKxN|I>
SCG NIjpXmJHfW6ldHnvckBCe3OjeR?= NXroRoZSOTByIN88UeKh NYTCNoo1TE2VTx?= NIjndFdz\WS3Y3XzJJRp\SCneHPpeIFjcWyrdImgc4YhW0OJIH7leZJwdnN? MV[yOVk3OjF|Mh?=
PCCL3 NFjzNGlHfW6ldHnvckBCe3OjeR?= NYHQSIxPOTBiwsXN M37rU|I1KGh? NXTzb3pv\W6qYX7j[ZMhTHWReEKgdJJwdW:2ZYKgeJJidnOlcnnweIlwdiCjY4Tpeol1gcLi4pEL M2\QRVI2QTZyOUW2
3T3-L1 preadipocytes MkjpSpVv[3Srb36gRZN{[Xl? MXSxNEDPxE4EoB?= Ml\DNVIhcA>? MX7pcoR2[2W|IFPSSWIheGixc4Doc5J6dGG2aX;uJIFv\CCFL1XCVO6zKGW6cILld5Nqd25? NFyzcGgzPTl{OEC1PC=>
H295R  M1HMVGZ2dmO2aX;uJGF{e2G7 NWi4SlNWOTEEoN88US=> NInxfnk1QMLiaB?= M1\Dc4lv[3KnYYPld{B{fGW{b3nkJI1mfGGkb3zpeIV{KGmwIITo[UBidmS{b3flckwhdWmwZYLhcI8uKGGwZDDncJVkd2OxcoTpZ49q\CCyYYToe4F6ew>? M{WycFI2QDZ7NUW2
PBMC M33iO2Z2dmO2aX;uJGF{e2G7 MlnEOVDDqM7:TR?= MnnYNlTDqGkEoB?= MUHpcohq[mm2czD0bIUhcW6lcnXhd4VlKHOnY4LleIlwdiCxZjDUUmYhcW6mdXPl[EBjgSC2aHWgSHBG MXuyOVg3PjB5OR?=
GLUTag  NEKydmNHfW6ldHnvckBCe3OjeR?= NVnYbWZ[OTEkgJpCuW0> MnHMNE8zNzRiaB?= MWrzeIlufWyjdHXzJGdNWC1zIIPlZ5JmfGmxbjDjc5Rz\WG2ZXSge4l1cCCLQl3Y MXmyOVg{OjZ|MR?=
GLUTag  NHewWGxHfW6ldHnvckBCe3OjeR?= M{DDW|Ex6oDLwsXN NYHXSHdkPCCq MnWxbY5kemWjc3XzJJRp\SCyQ2LFRkBt\X[nbIOge4l1cCC2aHWgTWJOYA>? NH;hXJczPTh|Mk[zNS=>
BAECs NXjFS|VITnWwY4Tpc44hSXO|YYm= MoHCNlUh|ryP M2W2fVI1KGh? MmP3[Y5p[W6lZYOgeIhmKGGldHn2ZZRqd25ib3[gVHBCWs7zIHL5JFUh|ryPIILld5ZmemG2cn;sMEBVPEiVLDDvdkA1NVCDUB?= MViyOVc6QDh{Nh?=
PC12 M3LGeGZ2dmO2aX;uJGF{e2G7 NU\Ye|QyOjYEoN88US=> MoDFOFghcA>? M{LHZYFkfGm4YYTld{BkSU2S MXGyOVc3QTNyNR?=
GH3 NIK4S4hHfW6ldHnvckBCe3OjeR?= NESxV4wyyqEQvF2= NEPMS2g3NWh? NVXq[ZlN[XS2ZX71ZZRmeyC2aHWgZ49zemWuYYTpc44h[mW2d3XlckBRWkxiYX7kJGJu[WxzIHX4dJJme3Orb36= NHzpXIMzPTd{N{CxPC=>
GH3 NHLBZ2lHfW6ldHnvckBCe3OjeR?= NVO3[IpJOcLizszN M2fpVVYucA>? MUDpcoR2[2W|IGDSUEBidmRiQn3hcFEtKGK3dDDuc5QhS2yxY3usJI1TVkFiZYjwdoV{e2mxbh?= NUnm[nZQOjV5MkewNVg>
BeWo M1jvXGZ2dmO2aX;uJGF{e2G7 M4[yRlEx6oDMzszNxsA> NHHrNXk4OiCq MYXEUXNQ NIDNWXNu\WSrYYTld{BD\VexIHPlcIwh\GmoZnXy[Y51cWG2aX;u NHTzVmgzPTdzM{SyOS=>
oocytes MWTGeY5kfGmxbjDBd5NigQ>? MXi1JO69VQ>? NH[xcYwzPCCq MWfheJRmdnWjdHXzJJJpNWmwc4XsbY4h[WO2aX;uJI9vKG:xY4n0[UBIXkKGIIPp[45q\mmlYX70cJnDqA>? NHHP[HczPTdyN{i1OC=>
SC MXvGeY5kfGmxbjDBd5NigQ>? NULTe21LOC53IN88US=> NULJS2cxOjRiaB?= NV7Z[JFydWmvaXPrd{B1cGViZX\m[YN1KG:oIHPBUXAh[W6jbH;nd{BwdiCRMTDhcoQhVUKSIHX4dJJme3Orb36= MUSyOVcxPTh5NB?=
SC M{HXXWZ2dmO2aX;uJGF{e2G7 NGS0fYMxNjVizszN NF;iXGI4OiCq MlPrbY5kemWjc3XzJIJwfGhiS4LvfE0zOCCjbnSgU|Eh\XiycnXzd4lwdiCrbjDhfI9vNXKnbHH0[YQhW0O|IHL1eEBwdmy7IFvyc5guOjEEoB?= NWS1fo4yOjV5MEW4O|Q>
UACC-647  NUjuNml2TnWwY4Tpc44hSXO|YYm= NFHHU|JFVVOR MULs[YFleyC2bzDhJJJqe2ViaX6gZ2FOWCCuZY\lcJMhMEWFNUFCpF3DqDJyLkO5xsDPxE1r M3Lt[lI2PzB|MEK1
UACC-647  M1fUS2Z2dmO2aX;uJGF{e2G7 MoSyNVDDqM7:TR?= MUWxOUBucW5? Ml\0SG1UVw>? MVPpcohq[mm2czDFVmsheGixc4Doc5J6dGG2aX;u M4HYXVI2PzB|MEK1
UACC-647  M2rMVWZ2dmO2aX;uJGF{e2G7 M{KxOFExyqEQvF2= NXSxZ5BCOTVibXnu Mmr1SG1UVw>? NEnpcGFqdmO{ZXHz[ZMh\UWIMjDwbI9{eGixconsZZRqd25ibHX2[Yx{yqB? MVGyOVcxOzB{NR?=
SH-SY5Y  MVLGeY5kfGmxbjDBd5NigQ>? NXXXfHBmOTEEoN88US=> MkPLNeKhcMLi MmH1bY5kemWjc3XzJGxWSyCjY4Tpeol1gQ>? Mo\1NlU2QTd2M{O=
SH-SY5Y  MnzwSpVv[3Srb36gRZN{[Xl? Mnq1NVDDqM7:TR?= MU[xxsBpyqB? MUDpcoNz\WG|ZYOgRWdEOSCvUl7BJIxmfmWu MnvUNlU2QTd2M{O=
hADSCs NWXzdIR2TnWwY4Tpc44hSXO|YYm= MkDjOgKBkcL3TR?= NUDBcHVyOzBibXnu NICxSIZqdmO{ZXHz[ZMh[0GPUDDs[ZZmdHN? NYO1WFI5OjV3OUG5NFg>
HEK293  MWnGeY5kfGmxbjDBd5NigQ>? M4DZd|XjiIoEtV2= M2K4dlMxKG2rbh?= NY\xZ4g5cW6lcnXhd4V{KGODTWCgcIV3\Wy| NWizeHVTOjV3OUG5NFg>
3T3-L1 MU\GeY5kfGmxbjDBd5NigQ>? M4HJRVIvPS93IN88US=> M1i3VlI1KGkEoB?= NVPofFVRe2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgRXRIVCCycn;0[YlvKGW6cILld5Nqd25iYYSgZYxtKGSxc3XzJJRme3SnZB?= MVqyOVU6ODV7Nx?=
OCI-Ly1  MVTGeY5kfGmxbjDBd5NigQ>? NV6xWmdpPDEEoN88US=> NVfsOlNZOcLiaNMg MVPEUXNQ M1Pid4lv\HWlZYOgeIhmKGmwY4LlcYVvfCCxZjDjRW1RKGOxbnPlcpRz[XSrb37z M2DjS|I2PTd4MkKw
OCI-Ly18  NEmzeVlHfW6ldHnvckBCe3OjeR?= Mk\4OFDDqM7:TR?= NXf3UZZPOcLiaNMg NFHsWGhFVVOR M2ri[4lv\HWlZYOgeIhmKGmwY4LlcYVvfCCxZjDjRW1RKGOxbnPlcpRz[XSrb37z MVSyOVU4PjJ{MB?=
BeWo M4LsSGZ2dmO2aX;uJGF{e2G7 NEfkblMzOMLiwsXN M3q5Z|Q5yqCq NWf0SWY{TE2VTx?= NVe5eFFycW6lcnXhd4V{KHSqZTDkbYZn\XKnboTpZZRqd25ib3[gRoVYdyClZXzsdy=> NX\XUWFDOjV3Nk[3OFA>
BeWo NIjwcHFHfW6ldHnvckBCe3OjeR?= MVSyNOKhyrWP MonBOFjDqGh? MUfEUXNQ MlfxbY5kemWjc3XzJJRp\SCjZHjld4lwdiCxZjDUTHAuOSCvb37vZ5l1\XN? MnjzNlU2PjZ5NEC=
LNCaP  MUfGeY5kfGmxbjDBd5NigQ>? NVuxflNTOTEEoN88US=> MkizNVIhcMLi MXnEUXNQ Mn7KbY5lfWOnczDhJIRz[W2jdHnjJIlv[3KnYYPlJI9nKEOURVKxJIFkfGm4aYT5 M4fHe|I2PTR6MEm5
ThGCs  MYrGeY5kfGmxbjDBd5NigQ>? MXKxNQKBks7:TR?= NELPNIc16oDMaB?= NGnifpdifWevZX70d{BJUUZzQTDs[ZZmdHNidHjheEB4\XKnIIP0bY12dGG2ZXSgZpkhS2:FbEK= M2TIWVI2PDN|MEK3
ThGCs  MWPGeY5kfGmxbjDBd5NigQ>? NWfsfGdPOTEkgJtOwG0> NWXJclU2POLCini= NFXpe|RqdmO{ZXHz[ZMhS2:FbEKtbY5lfWOnZDDFSG4zyqCpZX7lJIV5eHKnc4Ppc44> NYnUdHQyOjV2M{OwNlc>
ThGCs  MXvGeY5kfGmxbjDBd5NigQ>? NWezZ2ROOTEkgJtOwG0> MWOzJIg> NVnITpp5cW6qaXLpeJMhfGinIHXm[oVkfCCxZjDINm8zKG:wIFXEUlIhdVKQQR?= NEPqOZIzPTR|M{CyOy=>
RBMECs MYfGeY5kfGmxbjDBd5NigQ>? NXm0[3I5OC5yNT:wMlUwPSEQvF2= NUPyO|loOC5{NTDo NFjoVG9qdmO{ZXHz[ZMh[0GPUDDjc45k\W62cnH0bY9v NF;rXJUzPTRzNk[1NS=>
RBMECs Mn2wSpVv[3Srb36gRZN{[Xl? NXvI[|lXPcLizszN M1LhN|EhcA>? M1zjTYJtd2OtczD0bIUh[WO2aY\heIlwdiCxZjDSbI9CN1KRQ1ugbY5lfWOnZDDifUBGVUGSLVnJ MkO3NlU1OTZ4NUG=
RBMECs NIjxWmdHfW6ldHnvckBCe3OjeR?= MnrUOeKh|ryP MWixJIg> NVzsNJpxeHKndnXueJMhfGinIFXNRXAuUUlvaX7keYNm\CCWRVXSJJZidHWnIHTlZ5Jm[XOn NXzPV|FsOjV2MU[2OVE>
RBMECs NEjBd4pHfW6ldHnvckBCe3OjeR?= MYm1xsDPxE1? Ml\NNUBp MVvwdoV3\W62czD0bIUhcW6lcnXhd4UhcW5iSGLQJIZtfXhiYXPyc5N{KHSqZTDCWGIhcW6mdXPl[EBjgSBiRV3BVE1KUQ>? NIrEPJUzPTRzNk[1NS=>
RBMECs M3KzWGZ2dmO2aX;uJGF{e2G7 NHzWSIw2yqEQvF2= MVexJIg> NWLrXXFUcW6qaXLpeJMhfGinIHTlZ5Jm[XOnZDDv[kBidW:3boSgc4YhYk9vMTDpckBOTnNiaX7keYNm\CCkeTDFUWFRNUmL MoHiNlU1OTZ4NUG=
RBMECs NI\yPVZHfW6ldHnvckBCe3OjeR?= M3[0XVXDqM7:TR?= NXnaSodCOSCq MoTFdoV3\XK|ZYOgeIhmKGOqYX7n[ZMhcW5iWl:tNUBlcXO2cnnieZRqd25ic3XlckB4cXSqIFXNRXAuUUlidILlZZRu\W62 NFPWWXMzPTRzNk[1NS=>
RBMECs M2TaeWZ2dmO2aX;uJGF{e2G7 MUi1xsDPxE1? MUmxJIg> M4nEVoJtd2OtczD0bIUhTU2DUD3JTU1qdmS3Y3XkJINp[W6pZTDpckBOVENicHjvd5Bpd3K7bHH0bY9v MXuyOVQyPjZ3MR?=
RBMECs MoDLSpVv[3Srb36gRZN{[Xl? NELVbno2yqEQvF2= MV2xJIg> NFvpS5pjdG:la4OgeIhmKGGldHnuJIN6fG:|a3Xs[ZRwdiC{ZXHydoFv\2WvZX70JJNm\W5id3n0bEBGVUGSLVnJJJRz\WG2bXXueOKh MUSyOVQyPjZ3MR?=
Primary bovine chondrocytes MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rQSlXPxE1? NF7DbYw1QCCq MULy[ZZmenOnczD0bIUhcW6qaXLpeI9zgSCnZn\lZ5Qhd2ZiY3Xs[YNwgGmkIH;uJJBzd2yrZnXyZZRqd25iaX6g[5Jwf3SqIIDsZZRmKGOqb37kdo9kgXSncx?= NEHnUYQzPTRyNkCxOi=>
EM1  M1nCcGZ2dmO2aX;uJGF{e2G7 NYrjfYFkOTYkgJtOwG0> MUm0PEBp NFjaVYVz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBNUUcEoH;yxsBRXEeVMtMgbY7DqEODTGKtJI9zyqCHUFHDNk1{cWynbnPl[EBGVTFiY3XscJPDqA>? NEPZPZkzPTN5OE[2NS=>
BeWo  NInDdFZHfW6ldHnvckBCe3OjeR?= M124dFIxyqEEtV2= MUO0POKhcMLi NUPUbXB3TE2VT9Mg NIL4WGhqdmO{ZXHz[ZMhfGinIHLleIEucEOJIILlcIVie2V? MUGyOVM3OjJ4MB?=
BeWo  Ml;aSpVv[3Srb36gRZN{[Xl? M4KyNlIxyqEEtV2= M{P2XlQ5yqCqwrC= MWDEUXNQyqB? NV\GdXRt\G:5boLl[5Vt[XSnczD0bIUhdGW4ZXygc4YhXE2HTV[xOi=> MoXXNlU{PjJ{NkC=
BeWo  MX;GeY5kfGmxbjDBd5NigQ>? M3roclIxyqEEtV2= MV60POKhcMLi M2TCXWROW00EoB?= NIDTZ|Bld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBIS01vMR?= NVq5N5BkOjV|NkKyOlA>
granulosa cells NXLFdYN4TnWwY4Tpc44hSXO|YYm= NEfwUGQyOCEQvF2= MYWxNk8zPCCq MYHpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\sLiUlfTNuKhdVKQQR?= M2T5UFI2OzN7MUC1
granulosa cells M3rUSWZ2dmO2aX;uJGF{e2G7 NIDVOZAyOCEQvF2= NIC4enIyOi9{NDDo NV3mdHNkcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdoVxd3K2ZYKgZYN1cX[rdImg[o9zKHSqZTDsc45o\XO2IH\yZYdu\W62IDlijLI5PTRxK{G4VmdUOi6OVVOp NGrjZnczPTN|OUGwOS=>
granulosa cells NEnLO3FHfW6ldHnvckBCe3OjeR?= MofhNVAh|ryP NXy3WVhkOjRiaB?= NWPj[WRMcW6lcnXhd4V{KHSqZTDpcpRmdnOrdImgc4YhTE6DL4Dyc5RmcW5iY3;tdIxmgA>? MlPtNlU{OzlzMEW=
granulosa cells M3nqeGZ2dmO2aX;uJGF{e2G7 NUDuVXpVOTBizszN M{jNelI1KGh? M1HXUolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLHV|IheHKxbX;0[ZIh[WO2aY\peJk> NV\oT4k3OjV|M{mxNFU>
SK-N-AS  MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWXwPFJXOTBizszNxsA> NUPWNYJvOjRxNEigbC=> MmfM[Y5p[W6lZYOgeIlu\S2mZYDlcoRmdnSueTDj[YxtfWyjcjD2bYFjcWyrdIpCpC=> NYjXZnNUOjV{Nk[wOlM>
SK-N-AS  NIPEV5pHfW6ldHnvckBCe3OjeR?= MkLRNVAh|ryPwrC= NFT6VoYzPCCq M2nqXIlv[3KnYYPld{B1cGViY1HNVEBt\X[nbIRCpC=> NFuxeGMzPTJ4NkC2Ny=>
SK-N-AS  MW\GeY5kfGmxbjDBd5NigQ>? NIrHT5oyOCEQvF5CpC=> M1nJflI1KGh? M3XnSolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBkgWOuaX6gSFE> NYnZPWQzOjV{Nk[wOlM>
SK-N-AS  NXXoS5QxTnWwY4Tpc44hSXO|YYm= NVnxNlZqOTBizszNxsA> NX\jS|NCOzBibXnu MWPpcoR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjFOtk1k[XSnbnnuJEh{\XJ4N{WpMEBxNUeVS{ROtkApe2W{OTmgZY5lKGOxbnPvcYl1[W62IHjp[4hmeiCuZY\lcJMhd2ZiYXP0bZZmNCC3boDoc5NxcG:{eXzheIVlNCEQsj3jZZRmdmmw MVeyOVI3PjB4Mx?=
SK-N-AS  MlPnSpVv[3Srb36gRZN{[Xl? NH7ScJAyOCEQvF5CpC=> NH62NZMyOC9|MD:2NEBucW5? MV\pcoNz\WG|ZYOgcIV3\Wy|IH;mJJAu|rJvY3H0[Y5qdiBqc3XyOlc2MSCjbnSgbY5lfWOnczDhZ4N2dXWuYYTpc44hd2ZicD5Otk1k[XSnbnnuJEh{\XJ4N{WpJIlvKCiyZYLpLY52[2ynYYKgdoVocW:wcx?= NX7HdI9UOjV{Nk[wOlM>
SK-N-SH MkDDR4VtdCCYaXHibYxqfHliQYPzZZk> NUP1Uop4OTBizszNxsA> Mn\SOFghcA>? NHvZNWVmdmijbnPld{BUUy2QLWPIJI5mfXKxYnzhd5RwdWFiY3XscEB3cWGkaXzpeJk> M{nHS|I2OjZ4ME[z
HEK‐CFTR NEHsUHhHfW6ldHnvckBCe3OjeR?= MV2y5qCUPTEEoN88US=> MnL6NE0yOiCvaX6= MmfPSG1UV8Li MlHGbY5lfWOnczDhJIRwe2YkgKDk[ZBmdmSnboSgbY9lcWSnIHXm[ox2gMLi NELNbpYzPTJ4M{KwOy=>
L6 M4jv[2Z2dmO2aX;uJGF{e2G7 M{DNU|QxKML3TR?= MUSyOEBp MX3pcohq[mm2czDEUWgyNWmwZIXj[YQhSWu2IHHjeIl3[XSrb36= MmnJNlUzPDd3NUC=
MIN6  M1vQfmZ2dmO2aX;uJGF{e2G7 MX[xNEDPxE4EoB?= Ml7zN{Bp MUfpcoNz\WG|ZYOgSFMhdVKQQTDlfJBz\XO|aX;u MoL1NlUzPDFzMkS=
ventricular cardiomyocytes  NUSyOpNWTnWwY4Tpc44hSXO|YYm= NG[0Z5IxNjBzLUGwJO69VQ>? MVPpcoNz\WG|ZYOgJINCVVBiYXPjeY12dGG2aX;u MoTMNlUzODNzMUO=
ventricular cardiomyocytes  M3XPU2Z2dmO2aX;uJGF{e2G7 NHzkZWIxNjBzLUGwJO69VQ>? Morm[ZZwc2W|IHHuJIlvd3S{b4DpZ{Bz\XOyb37z[UAyOjEEsUG1KUBi[m:4ZTDiZZNidCC5aYToJIFvKEWFNUFCpI9nKDJwMjFCuW0> MnP3NlUzODNzMUO=
BeWo  NEXBNo9HfW6ldHnvckBCe3OjeR?= MV6yNEDDvU1? M1zZPVQ5KGh? M3jpVWROW00EoB?= MkPkbY5lfWOnczDj[YxtKG[3c3nvci=> NInmZpMzPTF6NES3Oy=>
THP-1  MX;GeY5kfGmxbjDBd5NigQ>? NHHJSHQyNzFyIN88US=> MYmyxsBp NIDiO4hFVVORwrC= MkXId5VxeHKnc4Pld{BOS1BvMTDwdo9lfWO2aX;uxsA> NVL4[pNVOjVzNUS4PFI>
Huh-7 M2C4[GZ2dmO2aX;uJGF{e2G7 Mn:yNE0zOCEQvF2= MXuyJIjDqA>? NX7KcHJnemW|dXz0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KGmwY4LlZZNmKGmwIHOtUZlkKGW6cILld5Nqd25iYYSgeIhmKHC{b4TlbY4h[W6mIH3SUmEhdGW4ZXzz MUiyOVExQTh|NB?=
C6 MlvBSpVv[3Srb36gRZN{[Xl? M{TibVExKM7:TdMg MX2yNEBucW5? NETSRZNqdmO{ZXHz[ZMh[0GPUDDhZ4N2dXWuYYTpc44> NH61[mUzPTB4OUSxOy=>
SW480 M{fsO2Z2dmO2aX;uJGF{e2G7 NVfuSHJXPDEEoN88US=> NXflZWZTPDkEoHi= MkTpSG1UVw>? NGDuZ3Bi[3SrdnH0[ZMhWFB{QR?= M4HOblI1QTl5NEWx
HT-29  NVTLUVUzTnWwY4Tpc44hSXO|YYm= NYr2ZWd[PDEEoN88US=> NXHWb25sPDkEoHi= MoXvSG1UVw>? MXzhZ5RqfmG2ZYOgVHAzSQ>? M1e0dlI1QTl5NEWx
SW480 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVy0NOKh|ryP M{n1[FAuPzJiaB?= Mk\MSG1UVw>? M373RYlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> MlzGNlQ6QTd2NUG=
HT-29  MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLaUHA1OMLizszN NGO1[GgxNTd{IHi= NHPyd3pFVVOR NGn0[XpqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 MVuyOFk6PzR3MR?=
SW480 MVzGeY5kfGmxbjDBd5NigQ>? MYS0NOKh|ryP NUHibXVXPyCm M37HOWROW09? MWfy[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi NHe2TGUzPDl7N{S1NS=>
HT-29  NH;USINHfW6ldHnvckBCe3OjeR?= M3XufFQxyqEQvF2= NUTmTo5iPyCm MkjjSG1UVw>? NFTCZYRz\WS3Y3XzJINwdG:wb4PwbIVz\SCob4LtZZRqd25iY3HwZYJqdGm2edMg MlLZNlQ6QTd2NUG=
SW480 NYfNZXhQSXCxcITvd4l{KEG|c3H5 MYG0NOKh|ryP M4DKc|Q5yqCq Ml\wSG1UVw>? MVPpcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= MY[yOFk6PzR3MR?=
HT-29  NWrUdHA4SXCxcITvd4l{KEG|c3H5 MoXSOFDDqM7:TR?= MlTqOFjDqGh? MUPEUXNQ M4fLfIlv\HWlZYOgZY4h[WO2aY\heIlwdiCxZjDjZZNx[XOnIEOvOy=> M2TTSFI1QTl5NEWx
SW480 MoTERZBweHSxc3nzJGF{e2G7 Mm\SOFDDqM7:TR?= MlfVOFjDqGh? M3HhdmROW09? MVzpcoR2[2W|IHPoZY5o\XNiaX6geIhmKHCqb4PwbI9zgWyjdHnvckB{fGG2dYOgc4YhWFB{QTD0ZZJo\XS| NXXzbm5POjR7OUe0OVE>
HT-29  MXPBdI9xfG:|aYOgRZN{[Xl? M1TCflQxyqEQvF2= NHrleYg1QMLiaB?= NIq4SoJFVVOR MknYbY5lfWOnczDjbIFv\2W|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?= MojTNlQ6QTd2NUG=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 410.5
化学式

C22H34O7

CAS No. 66575-29-9
保管
in solvent
別名 Coleonol
Smiles CC(=O)OC1C(O)C2C(C)(C)CCC(O)C2(C)C3(O)C(=O)CC(C)(OC13C)C=C

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

cAMPシグナル伝達経路

Tags: Forskolinを買う | Forskolin ic50 | Forskolin供給者 | Forskolinを購入する | Forskolin費用 | Forskolin生産者 | オーダーForskolin | Forskolin化学構造 | Forskolin分子量 | Forskolin代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID